来氟米特与雷公藤多苷治疗IgA肾病对照研究  

Control study Lefunomide and triptolide in treating IgA nephropathy

作　　者：常靖[1] 张文娟[1] 宋修芹 邱晓军[1] 袁东[1] 郑烟平 

机构地区：[1]烟台市烟台山医院肾内科,264000

出　　处：《中国实用医药》2011年第25期9-10,共2页China Practical Medicine

摘　　要：目的观察来氟米特(LEF)、雷公藤多苷联合激素治疗IgA肾病的疗效和安全性。方法收集符合条件的60例中等量蛋白尿IgA肾病患者随机分为2组,试验组LEF联合中等量激素治疗,对照组雷公藤多苷联合中等量激素治疗,观察治疗前、后1、3、6个月的相关临床指标变化,并进行评价。结果试验组治疗后24h尿蛋白定量显著减少(P<0.01),血清白蛋白显著升高(P<0.01),完全缓解率为46.4%,总有效率为85.7%。与对照组比较疗效差异无统计学意义(P>0.05)。观察组起效快,不良反应轻微,患者耐受性好。结论来氟米特联合激素可以作为治疗IgA肾病的选择之一,且安全、有效。Objective To investigate the infects and safety of Lefunomide（LEF） combined with medium dose gIucocorticoid, and TriptoIide with medium dose gIucoeorticoid for IgA nephropathy with medium albuminuria. Methods Sixty patients with IgA nephropathy with medium albuminuria were devided into two groups at random. The patients in test group were treated with LEF combined with medium dose glucocorticoid. The patients in control group received Triptolide with medium dose glucocorticoid. Clinical data were observed and evaluated in months 1,3 and 6 during the treatment. Results After receiving LEF therapy, the proteinuria in the test group decreased siganificantly （P 〈 0. 01 ） and serum albumin increased significantly （ P 〈 0. 01 ）. The complete relieving rate was 46.4% ,the total efficient rate was 85. 7%. Contracted with triptolide, the efficiency of LEF on treating IgA nephropathy was not statistically different （P 〉 0. 05 ）. LEF can act more quickly than triptolide, the side effects were mild and all patients tolerated this therapy. Conclusion LEF combined with medium dose glucocorticoid therapy can be one of the safety and effective choices for treatment of IgA nephropathy.

关 键 词：来氟米特 IGA肾病 雷公藤多苷 

分 类 号：R692.3[医药卫生—泌尿科学]